Literature DB >> 15207817

PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma.

Arne Ostman1.   

Abstract

PDGFs and their cognate tyrosine kinase alpha- and beta-receptors are involved in multiple tumor-associated processes including autocrine growth stimulation of tumor cells, stimulation of tumor angiogenesis and recruitment and regulation of tumor fibroblasts. The recent development of clinically useful PDGF antagonists, like STI571/Glivec, has increased the interest in PDGF receptors as cancer drug targets. Autocrine PDGF receptor signaling occurs in certain malignancies characterized by mutational activation of PDGF or PDGF receptors, for instance, dermatofibrosaracoma protuberans, gastrointestinal stromal tumors, and hypereosinophilic syndrome. The roles of PDGF in regulation of tumor angiogenesis and tumor fibroblasts are more general, and probably occur in most common solid tumors. Concerning tumor angiogenesis recent studies have predominantly focused on the importance of PDGF receptor signaling for tumor pericyte recruitment. PDGF receptors in the tumor stroma have also attracted attention as interesting drug targets because of their function as regulators of tumor interstitial fluid pressure, tumor transvascular transport and tumor drug uptake. In summary, the improved understanding of the role of PDGF signaling in tumor biology, and the introduction of PDGF antagonists, has set the stage for a continued development of PDGF antagonists as novel cancer drugs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15207817     DOI: 10.1016/j.cytogfr.2004.03.002

Source DB:  PubMed          Journal:  Cytokine Growth Factor Rev        ISSN: 1359-6101            Impact factor:   7.638


  90 in total

1.  Structures of a platelet-derived growth factor/propeptide complex and a platelet-derived growth factor/receptor complex.

Authors:  Ann Hye-Ryong Shim; Heli Liu; Pamela J Focia; Xiaoyan Chen; P Charles Lin; Xiaolin He
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-02       Impact factor: 11.205

2.  Understanding and targeting resistance to anti-angiogenic therapies.

Authors:  Jeffrey M Clarke; Herbert I Hurwitz
Journal:  J Gastrointest Oncol       Date:  2013-09

Review 3.  Role of platelet-derived growth factors in physiology and medicine.

Authors:  Johanna Andrae; Radiosa Gallini; Christer Betsholtz
Journal:  Genes Dev       Date:  2008-05-15       Impact factor: 11.361

Review 4.  Fibroblast growth factor regulation of neovascularization.

Authors:  Masahiro Murakami; Michael Simons
Journal:  Curr Opin Hematol       Date:  2008-05       Impact factor: 3.284

5.  Inhibition of receptor signaling and of glioblastoma-derived tumor growth by a novel PDGFRβ aptamer.

Authors:  Simona Camorani; Carla L Esposito; Anna Rienzo; Silvia Catuogno; Margherita Iaboni; Gerolama Condorelli; Vittorio de Franciscis; Laura Cerchia
Journal:  Mol Ther       Date:  2014-01-02       Impact factor: 11.454

Review 6.  Pharmacological targeting of the PDGF-CC signaling pathway for blood-brain barrier restoration in neurological disorders.

Authors:  Sebastian A Lewandowski; Linda Fredriksson; Daniel A Lawrence; Ulf Eriksson
Journal:  Pharmacol Ther       Date:  2016-08-12       Impact factor: 12.310

Review 7.  Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies.

Authors:  Nikhil G Thaker; Ian F Pollack
Journal:  Expert Rev Neurother       Date:  2009-12       Impact factor: 4.618

8.  Intratumoral heterogeneity for expression of tyrosine kinase growth factor receptors in human colon cancer surgical specimens and orthotopic tumors.

Authors:  Toshio Kuwai; Toru Nakamura; Sun-Jin Kim; Takamitsu Sasaki; Yasuhiko Kitadai; Robert R Langley; Dominic Fan; Stanley R Hamilton; Isaiah J Fidler
Journal:  Am J Pathol       Date:  2008-01-17       Impact factor: 4.307

9.  Human uterine leiomyoma-derived fibroblasts stimulate uterine leiomyoma cell proliferation and collagen type I production, and activate RTKs and TGF beta receptor signaling in coculture.

Authors:  Alicia B Moore; Linda Yu; Carol D Swartz; Xaiolin Zheng; Lu Wang; Lysandra Castro; Grace E Kissling; David K Walmer; Stanley J Robboy; Darlene Dixon
Journal:  Cell Commun Signal       Date:  2010-06-10       Impact factor: 5.712

10.  Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma.

Authors:  D A Reardon; G Dresemann; S Taillibert; M Campone; M van den Bent; P Clement; E Blomquist; L Gordower; H Schultz; J Raizer; P Hau; J Easaw; M Gil; J Tonn; A Gijtenbeek; U Schlegel; P Bergstrom; S Green; A Weir; Z Nikolova
Journal:  Br J Cancer       Date:  2009-11-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.